Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis
Double-Blind, Triple Dummy, Parallel-Group, Randomized, Six-Month Study To Compare Celecoxib (200 Mg BID) With Diclofenac Sr (75 Mg BID) Plus Omeprazole (20 Mg QD) For Gastrointestinal Events In Subjects With Osteoarthritis And Rheumatoid Arthritis At High-Risk Of Gastrointestinal Adverse Events
Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
This PHASE4 trial investigates Arthritis, Rheumatoid and Osteoarthritis and is currently completed. Pfizer's Upjohn has merged with Mylan to form Viatris Inc. leads this study, which shows 9 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Change History
9 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Dec 2025 [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Apr 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jan 2021 — Apr 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Oct 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aldershot, United Kingdom, Alkmaar, Netherlands, Alytus, Lithuania, Amiens, France, Ashford, United Kingdom, Aston Clinton, United Kingdom, Bangalore, India, Barakaldo, Spain, Barcelona, Spain, Barranquilla, Colombia and 133 more location s